Enzyvant Therapeutics

Bill Symonds, Ph.D., CEO

Oct. 12 | 5:30pm | UBC Ballroom  

Cambridge, MA 

(Private) 

In-person Presentation 

Enzyvant is a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases. The company’s first commercial product is FDA-approved RETHYMIC® (allogeneic processed thymus tissue-agdc), a tissue-based regenerative therapy for an ultra-rare and life-threatening pediatric immunodeficiency. Enzyvant has distinctive capabilities in expedited development of regenerative therapies for rare diseases. The company has obtained and leveraged multiple regulatory designations including Regenerative Medicine Advanced Therapy, Breakthrough, Fast Track, Rare Pediatric Disease, Orphan Drug, and Advanced Therapies Medicinal Product. Enzyvant is wholly owned by Sumitovant Biopharma (wholly owned by Sumitomo Dainippon Pharma Co.). 

www.enzyvant.com 

 



By using this website you agree to accept our Privacy Policy and Terms & Conditions